Form 4: Acrivon Therapeutics Chief Legal Officer Reports Tax Withholding Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On January 17, 2025, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction on SEC Form 4.
- The transaction involved the withholding of 659 common stock shares to satisfy tax obligations related to the vesting of restricted stock units.
- The price per share for the withholding was $5.78.
- Following the transaction, Miller directly owns 37,282 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a standard transaction related to tax obligations. It doesn't indicate positive or negative sentiment.
Industry Context
This is a routine filing related to executive compensation and tax obligations, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of the transaction (stock withholding for tax obligations). |
| 01/22/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.